摘要
目的 观察不同程度的充血性心力衰竭 (CHF)患者血浆肾上腺升压素 (ADT)的变化和药物治疗对其影响。方法 采用特异性放射免疫法检测 45例CHF患者药物治疗前后ADT血浆浓度。结果 ADT血浆浓度在Ⅱ级心功能为 ( 2 9.98± 1.13 ) pg/ml,Ⅲ级为 ( 3 3 .45± 0 .91) pg/ml,Ⅳ级为 ( 2 0 .71± 0 .75 )pg/ml,Ⅲ级时达到高峰 ,Ⅳ级时明显下降 ,并且低于对照组的 [( 2 4.89±2 .19) pg/ml] ,心衰各亚组与对照组比较 ,差异均有显著性 (P均 <0 .0 5 ) ;经 7天抗心衰治疗后 ,Ⅲ级组患者血浆ADT含量明显下降 (P <0 .0 5 ) ,Ⅱ、Ⅳ级组与治疗前比较无明显变化。结论 ADT参与了心衰的病理进程 ,可能反应心衰的严重程度 ,可作为心衰患者心功能的一种较好评价指标 ;
Objective To observe the changes of plasma adrenotensin(ADT)levels and clinical significance in the pathological process of congestive heart failure(CHF).Methods Plasma levels of ADT in 45 patients with CHF before and after treatment were measured by specific radioimmunoassay.Results Before treatment, plasma levels of ADT in class Ⅱ and Ⅲ in patients with CHF were(29.98± 1.13)pg/ml,(33.45±0.91)pg/ml,respectively,which were higher than those of in control group(24.89±2.19 )pg/ml,respectively(P<0.05).Plasma levels of ADT in class Ⅳ were(20.71±0.75)pg/ml,which were lower than those of class Ⅱ?Ⅲand control subjects(P<0.05).After treatment,plasma levels of ADT in classⅢ were much lower than those of before treatment(P<0.05).There was no significance of plasma levels of ADT in other classes compared with those of before treatment.Conclusion ADT might commonly be involved in the development of CHF and may serve as an assess index.Short-term medicine treatment can decrease the plasma levels of ADT.
出处
《临床内科杂志》
CAS
北大核心
2003年第12期639-641,共3页
Journal of Clinical Internal Medicine
基金
国家重点基础研究发展规划项目基金资助课题(G2 0 0 0 0 5690 5)
